Mary M. Rozenman
Finanzdirektor/CFO bei Insitro, Inc.
Profil
Mary M.
Rozenman is currently the Director at Tessera Therapeutics, Inc. and also holds a current position as Chief Financial & Business Officer at Insitro, Inc. She previously worked as a Director at Esperion Therapeutics, Inc. and CardioDx, Inc. She was also a Partner at McKinsey & Co., Inc. from 2008 to 2012.
From 2015 to 2019, she served as Senior VP-Corporate Development & Strategy at Aimmune Therapeutics, Inc. Dr. Rozenman holds a doctorate degree from Harvard University and an undergraduate degree from Columbia College (California).
Aktive Positionen von Mary M. Rozenman
Unternehmen | Position | Beginn |
---|---|---|
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 15.06.2021 |
Insitro, Inc.
Insitro, Inc. BiotechnologyHealth Technology Insitro, Inc. engages in engages in the discovery and development of drug products. Its approach include population scale data, cell-based disease models, biology at scale, cutting-edge machine learning, and predictive insights and new medicines. The company was founded by Daphne Koller and is headquartered in Portola Valley, CA. | Finanzdirektor/CFO | - |
Ehemalige bekannte Positionen von Mary M. Rozenman
Unternehmen | Position | Ende |
---|---|---|
AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2019 |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 31.12.2012 |
CARDIODX INC | Direktor/Vorstandsmitglied | - |
ESPERION THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Mary M. Rozenman
Harvard University | Doctorate Degree |
Columbia College (California) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ESPERION THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
CardioDx, Inc.
CardioDx, Inc. Medical/Nursing ServicesHealth Services CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA. | Health Services |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Health Technology |
Insitro, Inc.
Insitro, Inc. BiotechnologyHealth Technology Insitro, Inc. engages in engages in the discovery and development of drug products. Its approach include population scale data, cell-based disease models, biology at scale, cutting-edge machine learning, and predictive insights and new medicines. The company was founded by Daphne Koller and is headquartered in Portola Valley, CA. | Health Technology |